CU23405A1 - Composiciones farmacéuticas para uso terapéutico - Google Patents

Composiciones farmacéuticas para uso terapéutico

Info

Publication number
CU23405A1
CU23405A1 CU20030240A CU20030240A CU23405A1 CU 23405 A1 CU23405 A1 CU 23405A1 CU 20030240 A CU20030240 A CU 20030240A CU 20030240 A CU20030240 A CU 20030240A CU 23405 A1 CU23405 A1 CU 23405A1
Authority
CU
Cuba
Prior art keywords
pharmaceutical compositions
hepatitis
therapeutic use
diseases
antigen
Prior art date
Application number
CU20030240A
Other languages
English (en)
Inventor
Peter Vanlandshoot
Cano Carlos Duarte
Obregon Julio Cesar Alvarez
Gomez Raimundo Ubieta
Mato Yadira Lobaina
Gonzalez Daymir Garcia
Rivero Nelson Acosta
Carrera Santiago Duenas
Perez Enrique Iglesias
Rubido Julio Cesar Aguilar
Nieto Gerardo Enrique Guillen
Gonzalez Verena Lucila Muzio
Martinez Luis Saturnin Herrera
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20030240A priority Critical patent/CU23405A1/es
Priority to ARP040103654A priority patent/AR046063A1/es
Priority to KR1020067008110A priority patent/KR20060117920A/ko
Priority to CA002542680A priority patent/CA2542680A1/en
Priority to EP04762299A priority patent/EP1676587A1/en
Priority to CNA2004800341532A priority patent/CN1882359A/zh
Priority to BRPI0415654-4A priority patent/BRPI0415654A/pt
Priority to PCT/CU2004/000011 priority patent/WO2005037311A1/es
Priority to AU2004281098A priority patent/AU2004281098B2/en
Priority to RU2006117308/15A priority patent/RU2362586C2/ru
Priority to MXPA06004387A priority patent/MXPA06004387A/es
Priority to JP2006535932A priority patent/JP2007509081A/ja
Priority to US10/576,158 priority patent/US20070275012A1/en
Priority to ZA200603126A priority patent/ZA200603126B/xx
Publication of CU23405A1 publication Critical patent/CU23405A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Vacunas terapéuticas contra patógenos que causan enfermedades crónicas. Uso del antígeno de la superficie del virus de la hepatitis B (HbsAg), producido por vía recombinante a partir de Pichia pastoris, como componente principal, para la obtención de composiciones farmacéuticas con fines terapéuticos. Las mismas pueden comprender la combinación del antígeno de hepatitis b con otros antigenos coadministrados. Estas formulaciones son capaces de generar una potente respuesta linfoproliferativa y de linfocitos T citotóxicos, además de una considerable respuesta de anticuerpos específicos, lo que las hace muy efectivas para el tratamiento de estas enfermedades en humanos.
CU20030240A 2003-10-20 2003-10-20 Composiciones farmacéuticas para uso terapéutico CU23405A1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CU20030240A CU23405A1 (es) 2003-10-20 2003-10-20 Composiciones farmacéuticas para uso terapéutico
ARP040103654A AR046063A1 (es) 2003-10-20 2004-10-08 Composiciones farmaceuticas para uso terapeutico
KR1020067008110A KR20060117920A (ko) 2003-10-20 2004-10-20 치료용 약학적 조성물
CA002542680A CA2542680A1 (en) 2003-10-20 2004-10-20 Pharmaceutical compositions for therapeutic use
EP04762299A EP1676587A1 (en) 2003-10-20 2004-10-20 Pharmaceutical compositions for therapeutic use
CNA2004800341532A CN1882359A (zh) 2003-10-20 2004-10-20 用于治疗用途的药物组合物
BRPI0415654-4A BRPI0415654A (pt) 2003-10-20 2004-10-20 composições farmacêuticas para uso terapêutico, uso do antìgeno de superfìcie do vìrus da hepatite b, e, método para o tratamento de infecções por vìrus de progressão crÈnica
PCT/CU2004/000011 WO2005037311A1 (es) 2003-10-20 2004-10-20 Composiciones farmacéuticas para uso terapéutico
AU2004281098A AU2004281098B2 (en) 2003-10-20 2004-10-20 Pharmaceutical compositions for therapeutic use
RU2006117308/15A RU2362586C2 (ru) 2003-10-20 2004-10-20 Фармацевтические композиции для терапевтического применения
MXPA06004387A MXPA06004387A (es) 2003-10-20 2004-10-20 Composiciones farmaceuticas para uso terapeutico.
JP2006535932A JP2007509081A (ja) 2003-10-20 2004-10-20 治療用の医薬組成物
US10/576,158 US20070275012A1 (en) 2003-10-20 2004-10-20 Pharmaceutical Compositions for Therapeutic Use
ZA200603126A ZA200603126B (en) 2003-10-20 2006-04-19 Pharmaceutical compositions for therapeutic use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20030240A CU23405A1 (es) 2003-10-20 2003-10-20 Composiciones farmacéuticas para uso terapéutico

Publications (1)

Publication Number Publication Date
CU23405A1 true CU23405A1 (es) 2009-08-04

Family

ID=34441708

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20030240A CU23405A1 (es) 2003-10-20 2003-10-20 Composiciones farmacéuticas para uso terapéutico

Country Status (14)

Country Link
US (1) US20070275012A1 (es)
EP (1) EP1676587A1 (es)
JP (1) JP2007509081A (es)
KR (1) KR20060117920A (es)
CN (1) CN1882359A (es)
AR (1) AR046063A1 (es)
AU (1) AU2004281098B2 (es)
BR (1) BRPI0415654A (es)
CA (1) CA2542680A1 (es)
CU (1) CU23405A1 (es)
MX (1) MXPA06004387A (es)
RU (1) RU2362586C2 (es)
WO (1) WO2005037311A1 (es)
ZA (1) ZA200603126B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
BR112020005695A2 (pt) 2017-10-05 2020-10-06 Toko Yakuhin Kogyo Co., Ltd. composição da vacina da hepatite b nasal e método para produzir a mesma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22290A1 (es) * 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
DE69926342T2 (de) * 1998-02-03 2006-01-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lieferung von immunogenen molekülen unter verwendung von hbsag partikeln
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes

Also Published As

Publication number Publication date
EP1676587A1 (en) 2006-07-05
RU2006117308A (ru) 2007-12-10
KR20060117920A (ko) 2006-11-17
BRPI0415654A (pt) 2006-12-19
AU2004281098B2 (en) 2009-06-25
ZA200603126B (en) 2007-02-28
CN1882359A (zh) 2006-12-20
CA2542680A1 (en) 2005-04-28
RU2362586C2 (ru) 2009-07-27
WO2005037311A1 (es) 2005-04-28
AR046063A1 (es) 2005-11-23
JP2007509081A (ja) 2007-04-12
AU2004281098A1 (en) 2005-04-28
US20070275012A1 (en) 2007-11-29
MXPA06004387A (es) 2006-06-14

Similar Documents

Publication Publication Date Title
CY1121211T1 (el) Εμβολιο ιου ερπητα ζωστηρα
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
MX2008013993A (es) Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
UY28084A1 (es) Derivados antivirales de nucleosidos
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
UY27466A1 (es) Métodos y composiciones para el tratamiento de hepatitis c virus con 4'-modificaciones nucleosides
AR061894A1 (es) Vacunas para malaria
ECSP15007345A (es) Métodos para el tratamiento de infecciones de hepatitis b y hepatitis d
CY1105408T1 (el) Χρησιμοποιηση στελεχων του ιου parapox ovis για την παρασκευη αντιικων φαρμακων και φαρμακων κατα του καρκινου
PA8744101A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
CY1110744T1 (el) Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
ES2351489T3 (es) Vacunas mejoradas.
ATE375804T1 (de) Ribavirin-enthaltende vakzine
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
AR052639A1 (es) Composicion vacunal contra el virus de la hepatitis c.
WO2006045616A3 (en) β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
CU23405A1 (es) Composiciones farmacéuticas para uso terapéutico
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
AR059648A1 (es) Antigenos vacunales quimericos contra el virus de la peste porcina clasica
JP2016520077A5 (es)
AR038311A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
UY31574A1 (es) Vacunas contra la malaria